Cargando…
Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records
PURPOSE: To describe attrition patterns of opioid use disorder (OUD) patients treated with buprenorphine (BUP) and to assess how clinical, sociodemographic, or BUP medication dosing features are associated with attrition. PATIENTS AND METHODS: Electronic health records of adults (16+ year-olds) with...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560173/ https://www.ncbi.nlm.nih.gov/pubmed/34737569 http://dx.doi.org/10.2147/NDT.S331442 |
_version_ | 1784592887546118144 |
---|---|
author | Ker, Sheryl Hsu, Jennifer Balani, Anisha Mukherjee, Sankha Subhra Rush, A John Khan, Mehreen Elchehabi, Sara Huffhines, Seth DeMoss, Dustin Rentería, Miguel E Sarkar, Joydeep |
author_facet | Ker, Sheryl Hsu, Jennifer Balani, Anisha Mukherjee, Sankha Subhra Rush, A John Khan, Mehreen Elchehabi, Sara Huffhines, Seth DeMoss, Dustin Rentería, Miguel E Sarkar, Joydeep |
author_sort | Ker, Sheryl |
collection | PubMed |
description | PURPOSE: To describe attrition patterns of opioid use disorder (OUD) patients treated with buprenorphine (BUP) and to assess how clinical, sociodemographic, or BUP medication dosing features are associated with attrition. PATIENTS AND METHODS: Electronic health records of adults (16+ year-olds) with OUD treated with BUP from 23 different substance use or mental health care programs across 11 US states were examined for one year following BUP initiation in inpatient (IP), intensive outpatient (IOP), or outpatient (OP) settings. Treatment attrition was declared at >37 days following the last recorded visit. Survival analyses and predictive modelling were used. RESULTS: Retention was consistently 2–3 times higher following BUP initiation in OP (n = 2409) than in IP/IOP (n = 2749) settings after 2 (50% vs 25%), 6 (27% vs 9%) and 12 months (14% vs 4%). Retention was higher for females, whites (vs blacks), and those with less severe OUD, better global function, or not using non-psychotropic medications. Comorbid substance use, other psychiatric disorders, and the number of psychotropic medications were variously related to retention depending on the setting in which BUP was initiated. Predictive modelling revealed that a higher global assessment of functioning and a smaller OUD severity based on the Clinical Global Impression – Severity led to longer retentions, a higher initial BUP dose led to higher retention in a few cases, an OP setting of BUP initiation led to longer retentions, and a lower total number of psychotropic and non-psychotropic medications led to longer retentions. These were the most important parameters in the model, which identified 75.2% of patients who left BUP treatment within three months post-initiation, with a precision of 90.5%. CONCLUSION: Of all the OUD patients who began BUP, 50–75% left treatment within three months, and most could be accurately identified. This could facilitate patient-centered management to better retain OUD patients in BUP treatment. |
format | Online Article Text |
id | pubmed-8560173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-85601732021-11-03 Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records Ker, Sheryl Hsu, Jennifer Balani, Anisha Mukherjee, Sankha Subhra Rush, A John Khan, Mehreen Elchehabi, Sara Huffhines, Seth DeMoss, Dustin Rentería, Miguel E Sarkar, Joydeep Neuropsychiatr Dis Treat Original Research PURPOSE: To describe attrition patterns of opioid use disorder (OUD) patients treated with buprenorphine (BUP) and to assess how clinical, sociodemographic, or BUP medication dosing features are associated with attrition. PATIENTS AND METHODS: Electronic health records of adults (16+ year-olds) with OUD treated with BUP from 23 different substance use or mental health care programs across 11 US states were examined for one year following BUP initiation in inpatient (IP), intensive outpatient (IOP), or outpatient (OP) settings. Treatment attrition was declared at >37 days following the last recorded visit. Survival analyses and predictive modelling were used. RESULTS: Retention was consistently 2–3 times higher following BUP initiation in OP (n = 2409) than in IP/IOP (n = 2749) settings after 2 (50% vs 25%), 6 (27% vs 9%) and 12 months (14% vs 4%). Retention was higher for females, whites (vs blacks), and those with less severe OUD, better global function, or not using non-psychotropic medications. Comorbid substance use, other psychiatric disorders, and the number of psychotropic medications were variously related to retention depending on the setting in which BUP was initiated. Predictive modelling revealed that a higher global assessment of functioning and a smaller OUD severity based on the Clinical Global Impression – Severity led to longer retentions, a higher initial BUP dose led to higher retention in a few cases, an OP setting of BUP initiation led to longer retentions, and a lower total number of psychotropic and non-psychotropic medications led to longer retentions. These were the most important parameters in the model, which identified 75.2% of patients who left BUP treatment within three months post-initiation, with a precision of 90.5%. CONCLUSION: Of all the OUD patients who began BUP, 50–75% left treatment within three months, and most could be accurately identified. This could facilitate patient-centered management to better retain OUD patients in BUP treatment. Dove 2021-10-28 /pmc/articles/PMC8560173/ /pubmed/34737569 http://dx.doi.org/10.2147/NDT.S331442 Text en © 2021 Ker et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Ker, Sheryl Hsu, Jennifer Balani, Anisha Mukherjee, Sankha Subhra Rush, A John Khan, Mehreen Elchehabi, Sara Huffhines, Seth DeMoss, Dustin Rentería, Miguel E Sarkar, Joydeep Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records |
title | Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records |
title_full | Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records |
title_fullStr | Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records |
title_full_unstemmed | Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records |
title_short | Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records |
title_sort | factors that affect patient attrition in buprenorphine treatment for opioid use disorder: a retrospective real-world study using electronic health records |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560173/ https://www.ncbi.nlm.nih.gov/pubmed/34737569 http://dx.doi.org/10.2147/NDT.S331442 |
work_keys_str_mv | AT kersheryl factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords AT hsujennifer factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords AT balanianisha factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords AT mukherjeesankhasubhra factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords AT rushajohn factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords AT khanmehreen factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords AT elchehabisara factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords AT huffhinesseth factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords AT demossdustin factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords AT renteriamiguele factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords AT sarkarjoydeep factorsthataffectpatientattritioninbuprenorphinetreatmentforopioidusedisorderaretrospectiverealworldstudyusingelectronichealthrecords |